Clinical trial · Observational
Dalpiciclib in HR+/HER2- ABC
Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study
NCT06301438CI-TRIAL-00102313recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dalpiciclib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- dalpiciclib
- description
- dalpiciclib oral day 1-21, every 28 days
- interventionNames
- Drug: dalpiciclib
Primary outcomes (1)
- measure
- Progression-Free Survival
- timeFrame
- From the date of starting dalpiciclib to the date of first documentation of progression or death (up to approximately 1 years)
- description
- The time from the date of starting dalpiciclib to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
Secondary outcomes (1)
- measure
- Adverse events
- timeFrame
- From the date of starting dalpiciclib to the end of the treatment (up to approximately 1 year)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed advanced breast cancer * Hormone receptor-positive and human epidermal growth factor receptor 2-negative * ECOG 0-1 Exclusion Criteria: * Pregnant or breastfeeding * History of immunodeficiency
References
Publications (0)
Data not yet available
No reference posted for this study.